Figure 6.

Platelet responses to bacteria involve Tec kinase activation. Characterisation of platelet Tec phosphorylation in healthy controls (n=5), ibrutinib-untreated CLL (n=5) and ibrutinib-treated CLL (n=5) patients. Washed platelets from the three clinical groups were supplemented with fibrinogen and human IgG (commercially available IgGs pooled from healthy donors). Healthy control platelets were incubated in vitro with 5 μM ibrutinib, 15 μM acalabrutinib or vehicle for 5 minutes before adding agonists. Platelet samples were stimulated with either 3 μg/ml CRP-xl, S. aureus Newman or E. coli RS218. Relative phosphorylation of Tec was measured by a phospho-Tec ELISA. Data is shown as mean ± SD. Two-way ANOVA and Sidak’s multiple comparison test were used to compare CRP-xl responses across the three clinical groups. For the effect of ibrutinib on bacteria-induced phospho-Tec in healthy controls, one way ANOVA followed by Tukey’s multiple comparison correction was done. (*p ≤ 0.05, **p ≤ 0.01).